Gilead Says Overbroad Patent Doesn't Need Justices' Review
A Merck & Co. unit has overstated the effect of a Federal Circuit decision invalidating a patent tied to hepatitis C treatments, Gilead Sciences Inc. told the U.S. Supreme Court in...To view the full article, register now.
Already a subscriber? Click here to view full article